卡瑞利珠单抗联合甲磺酸仑伐替尼治疗中晚期肝细胞癌患者的效果

Effects of Camrelizumab combined with Lenvatinib mesylate in treatment of patients with middle-advanced hepatocellular carcinoma

目的:观察卡瑞利珠单抗联合甲磺酸仑伐替尼治疗中晚期肝细胞癌患者的效果。方法:选取2021年12月至2022年12月该院收治的86例中晚期肝细胞癌患者进行前瞻性研究,以随机数字表法将其分为对照组(n=43)和观察组(n=43)。对照组采用甲磺酸仑伐替尼治疗,观察组在对照组基础上联合卡瑞利珠单抗治疗,比较两组客观缓解率(ORR)、治疗前后肝功能指标[丙氨酸氨基转移酶(ALT)、碱性磷酸酶(ALP)、总胆红素(TBIL)、天门冬氨酸氨基转移酶(AST)]水平、血清学指标[可溶性血管细胞黏附因子1(sVCAM1)、血管内皮生长因子(VEGF)]水平和不良反应发生率。结果:观察组ORR为69.77%(30/43),高于对照组的48.84%(21/43),差异有统计学意义(P<0.05);治疗后,两组ALT、AST、TBIL、ALP、VEGF和sVCAM1水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:卡瑞利珠单抗联合甲磺酸仑伐替尼治疗中晚期肝细胞癌患者可提高ORR,降低肝功能指标和血清学指标水平,效果优于单纯甲磺酸仑伐替尼治疗。

Objective:To observe effects of Camrelizumab combined with Lenvatinib mesylate in treatment of patients with middleadvanced hepatocellular carcinoma.Methods:A prospective study was conducted on 86 patients with middle-advanced hepatocellular carcinoma admitted to this hospital from December 2021 to December 2022.They were divided into control group(n=43)and observation group(n=43)by using the random number table method.The control group was treated with Lenvatinib mesylate,while the observation group was treated with Camrelizumab on the basis of that of the control group.The objective response rate(ORR),the liver function indexes[alanine aminotransferase(ALT),alkaline phosphatase(ALP),total bilirubin(TBIL),aspartate aminotransferase(AST)]levels before and after the treatment,the serological indexes[soluble vascular cell adhesion factor 1(sVCAM1),vascular endothelial growth factor(VEGF)]levels,and the incidence of adverse reactions were compared between the two groups.Results:The ORR of the observation group was 69.77%(30/43),which was higher than 48.84%(21/43)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of ALT,AST,TBIL,ALP,VEGF and sVCAM1 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Camrelizumab combined with Lenvatinib mesylate in the treatment of the patients with middle-advanced=hepatocellular carcinoma can improve the ORR,reduce the levels of liver function indexes and serological indexes.Moreover,it is superior to single Lenvatinib mesylate treatment.